Started in 2001, Fallon Medica LLC is a leading scientific communications agency specializing in strategic launch initiatives and disease state education. We service the pharmaceutical and biotechnology industries, including specialty and rare disease markets. Specialty medicine and rare diseases require a deeper understanding of pathogenesis and the novel mechanisms of the orphan drugs designed to treat them. This level of complexity creates challenging educational needs for clinicians and patients, which is our focus. Whether it's launching a therapy that targets genetic mutations to pulmonologists or implicating the JAK pathway in rare cancers, we understand the issue is not only education, but how to effectively reach a disparate target. There are unique nuances in communicating with this market, and our experience speaks to our track record. We have successfully serviced the scientific communications needs for a number of different disease states, including:- Prostate Cancer- Cystic Fibrosis- LEMS- Polycythemia Vera- Macular Degeneration- Hemophilia- Myeloproliferative Fibrosis- Parkinson's Disease- EpilepsyOur capabilities include strategic communications planning and development, a full suite of training and educational tools for Medical Affairs organizations, Advocacy Platforms, including KOL planning and management, congress activities, literature gap analysis and message mapping, publication planning and execution, and all scientific content development. Our services extend as well to commercial teams, where we manage slide kit development for speaker training, advisory boards, and market development campaigns, in addition to a full portfolio of brand supporting tactics. Fallon Medica and its senior management has been led by Tim Fallon since 2001, who is the former CEO of a large New York based medical communications company and is also a founder of Medscape.